Keywords
Isquemia cerebral
Ratones
Agentes neuroprotectores
Regeneración nerviosa
Plasticidad neuronal
Trastornos psicomotores Fluoxetine
Brain ischemia
Mice
Neuroprotective agents
Nerve regeneration
Neuronal plasticity
Psychomotor disorders
How to Cite
Abstract
Introduction: fluoxetine is a drug of wide use in the treatment of mood disorders. In these conditions have been observed direct effects on neuronal plasticity and neuroregenerative properties. Objective: to evaluate the impact of fluoxetine over neurological impairment and ischemic volume in a model of brain ischemia. Design: we use 28 mice distributed into four experimental groups: fluoxetine and placebo with and without ischemic injury. Fluoxetine was administered by intraperitoneal injection at dose 20 mg/kg/day once daily for 21 days before ischemic surgery. The focal cerebral ischemia technique consist in enter through the internal carotid artery a monofilament nylon coated with poly-l-lysine until occlude middle cerebral artery, 30 minutes later the nylon is removed from the arterial, allowing vascular reperfusion. 24 hours after ischemia, the animals were behavioral neurological assessment using the modified Bederson scale and open-field behavioral test. After this, ischemic volume was determined using the method 2,3,5-Triphenyltetrazolium chloride. Results: mice treated with fluoxetine who underwent the procedure cerebral ischemia-reperfusion had a lower neurological deficit (p = 0.0001) and lower percentage of injury (p = 0.003), which was significantly correlated with improved of psychomotor disorders. Conclusions: fluoxetine seems to have a neuroprotective effect on cerebral isquemic in mouses. Our findings encourage us to continue studying its effect in future preclinical and clinical trials in patients with stroke and brain injury.
References
Kasner E, Saver J, Levine S. High lights from the 25th Annual International Stroke Conference. 2000; 10-12.
Brodaty H, Altendorf A, Withall A, Sachdev PS. Mortality and Institutionalization in Early Survivors of Stroke: The Effects of Cognition, Vascular Mild Cognitive Impairment, and Vascular Dementia. J Stroke Cerebrovasc Dis. 2010; 19):485-493. https://doi.org/10.1016/j.jstrokecerebrovasdis.2009.09.006
Hong KS, Saver JL. Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke. 2010; 41:471-477. https://doi.org/10.1161/STROKEAHA.109.571083
World Health Organization. Task Force on Stroke preventions and other Cerebrovascular Disorders: recommendation on stroke preventions, diagnosis and therapy. Stroke. 1989; 20: 1407-1431. https://doi.org/10.1161/01.STR.20.10.1407
Ratan RR. Beyond Neuroprotection to Brain Repair: Exploring the Next Frontier in Clinical Neuroscience to Expand the Therapeutic Window for Stroke. Transl Stroke Res. 2010; 1:71-73. https://doi.org/10.1007/s12975-010-0024-6
Singh A, Black SE, Herrmann N, Leibovitch FS, Ebert PL, Lawrence J, Szalai JP. Functional and neuroanatomic correlations in poststroke depression: the Sunnybrook Stroke Study. Stroke. 2000; 31: 637- 644. https://doi.org/10.1161/01.STR.31.3.637
Arango CA, Pimienta HJ, Escobar M. Depresión postisquemia cerebral: aproximación clínica y fisiopatológica. Revista Colombiana de Psiquiatría. 2000; 4: 321-344.
Paolucci S, Antonucci G, Grasso MG, Morelli D, Troisi E, Coiro P, De Angelis D, Rizzi F, Bragoni M. Poststroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis .2001; 12: 264- 271. https://doi.org/10.1159/000047714
Gillen R, Tennen H, McKee TE., Gernert-Dott P, Affleck G. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil. 2001; 82: 1645- 1649. https://doi.org/10.1053/apmr.2001.26249
Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003; 54: 376-387. https://doi.org/10.1016/S0006-3223(03)00423-2
Gupta A, Pansari K, Shetty H. Post-stroke depression. Int J Clin Pract. 2002; 56: 531- 537.
Lee HJ, Kim JW, Yim SV, Kim MJ, Kim SA, Kim YJ, Kim CJ, Chung JH. Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry. 2001; 610: 725-728. https://doi.org/10.1038/sj.mp.4000947
Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J. 1994; 8: 654- 660. https://doi.org/10.1096/fasebj.8.9.8005393
Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004; 64: 7562-7569. https://doi.org/10.1158/0008-5472.CAN-03-4046
Longa EZ, Wenstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989; 20: 84-91. https://doi.org/10.1161/01.STR.20.1.84
Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD. Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res. 1999; 833:181-190. https://doi.org/10.1016/S0006-8993(99)01528-0
Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986; 17: 472-476. https://doi.org/10.1161/01.STR.17.3.472
Yrjänheikki J, Koistinaho J, Kettunen M, Kauppinen RA, Appel K, Hüll M, Fiebich BL. Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. Brain Research. 2005; 1052: 174-179. https://doi.org/10.1016/j.brainres.2005.06.004
Wahl F, Allix M, Plotkine M, Boulu RG. Neurological and Behavioral Outcomes of Focal Cerebral Ischemia in Rats. Stroke. 1992; 23: 267-272. https://doi.org/10.1161/01.STR.23.2.267
Yang Y, Shuaib A, Li Q. Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method. Journal of Neuroscience Methods. 1998; 84: 9-16. https://doi.org/10.1016/S0165-0270(98)00067-3
Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with Image J. Biophotonics International. 2004; 11: 36-42.
Roulston CL, Callaway JK, Jarrott B, Woodman OL, Dusting GJ. Using behavior to predict stroke severity in conscious rats: post-stroke treatment with 3', 4'-dihydroxyflavonol improves recovery. Eur J Pharmacol. 2008; 584:100-10. https://doi.org/10.1016/j.ejphar.2008.01.046
Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001; 50: 718- 729. https://doi.org/10.1002/ana.1257
Haynes LE, Barber D, Mitchell IJ. Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum. Brain Res. 2004; 1026: 157-167. https://doi.org/10.1016/j.brainres.2004.05.117
Cavus I, Duman RS. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol Psychiatry. 2003; 54: 59-69. https://doi.org/10.1016/S0006-3223(03)00236-1
Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997; 54: 597-606. https://doi.org/10.1001/archpsyc.1997.01830190015002
Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry. 1998; 44: 324-335. https://doi.org/10.1016/S0006-3223(98)00031-6
Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, Yoon SH, Lee JY. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Research. 2009; 1281:108-116. https://doi.org/10.1016/j.brainres.2009.04.053
Kim DH, Li H, Yoo HL, Lee BH, Hwang IK, Won MH. Effects of fluoxetine on ischemic cells and expressions in BDNF and some antioxidants in the gerbil hippocampal CA1 region induced by transient ischemia. Experimental Neurology. 2007; 204: 748-758. https://doi.org/10.1016/j.expneurol.2007.01.008
Jacobs BL, Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry. 2000; 5: 262-269. https://doi.org/10.1038/sj.mp.4000712
Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000; 20: 9104 - 9110. https://doi.org/10.1523/JNEUROSCI.20-24-09104.2000
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Dumn R, Arancio O, Belzung C, Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003; 301:805-809. https://doi.org/10.1126/science.1083328
Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res. 2009; 87:1037-1045. https://doi.org/10.1002/jnr.21899
Ng SC, de la Monte SM, Conboy GL, Karns LR, Fishman MC. Cloning of human GAP-43: growth association and ischemic resurgence. Neuron. 1988; 1:133-139. https://doi.org/10.1016/0896-6273(88)90197-3
Stroemer RP, Kent TA, Hulsebosch CE. Neocortical neural sprouting, synaptogenesis, and behavioral recovery after neocortical infarction in rats. Stroke. 1995; 26: 2135-2144. https://doi.org/10.1161/01.STR.26.11.2135
Carmichael ST, Wei L, Rovainen CM, Woolsey TA. New patterns of intracortical projections after focal cortical stroke. Neurobiol Dis. 2001; 8: 910-922. https://doi.org/10.1006/nbdi.2001.0425
Chen J, Shen C, Meller E. 5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain. Eur J Pharmacol. 2002; 452:155-162. https://doi.org/10.1016/S0014-2999(02)02297-5
Dancause N, Barbay S, Frost SB, Plautz EJ, Chen D, Zoubina EV, Stowe AM, Nudo RJ. Extensive cortical rewiring after brain injury. J Neurosci. 2005; 25: 10167-10179. https://doi.org/10.1523/JNEUROSCI.3256-05.2005
Rola R, Mizumatsu S, Otsuka S, Morhardt DR. NobleHaeusslein LJ, Fishman K, Potts MB, Fike JR. Alterations in hippocampal neurogenesis following traumatic brain injury in mice. Experimental Neurology. 2006; 202: 189-199. https://doi.org/10.1016/j.expneurol.2006.05.034